EsoCap AG news
EsoCap has announced that scientists from the University of Greifswald have published important data regarding a hot-melt extrusion-based spinning process to produce pharmaceutical fibers and yarns. This spinning process is very useful in the context of EsoCap’s novel drug delivery technology, enabling targeted and long-lasting local therapy of the esophagus. The rapidly dissolving yarn is a key element in the innovative EsoCap system which enables local placement of drug-loaded films a
- EsoCap AG organized a multidisciplinary scientific advisory board meeting with eight international experts in Barrett’s esophagus (BE) in Zurich
- EsoCap’s technology for the topical treatment of Barrett’s esophagus was recognized by the experts for having high potential for clinical success
- EsoCap’s proprietary and unique targeted application technology for the upper gastrointestinal tract was shown to dramatically increa
“We are extremely pleased that The Medicine Maker is reporting on how EsoCap’s unique and innovative topical drug delivery system offers new treatment options for diseases of the esophagus,” said Isabelle Racamier, EsoCap AG CEO. “The interview is a great opportunity to highlight the challenges of esophageal disease and how EsoCap is innovating localized esophagus treatment”.
About The Medicine Maker
The development of new drugs and
“We are extremely pleased that Fierce Pharma Online reviewed EsoCap’s unique and innovative topical drug delivery system to the esophagus and the current Phase II program, as well as further use of its platform in additional indications,” said Isabelle Racamier, EsoCap AG CEO. “This strengthens our resolve to bring a major improvement to the lives of patients using EsoCap’s highly promising and innovative technology.”
About Fierce Pharma
- Randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients ongoing in four European countries with ESO-101
- ESO-101, EsoCap’s lead product candidate, consists of a capsule with a rolled, thin mucoadhesive film, loaded with the anti-inflammatory corticosteroid, mometasone furoate
- In a previous trial, EsoCap’s proprietary and unique targeted application technology for the upper gastrointestinal tract was shown to